ENGN Stock Forecast: enGene Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.76
−4.86% on the day

The 9 Wall Street analysts covering enGene Therapeutics, Inc. hold a median 12-month price target of $4 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 18 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$117.9M
Ticker Nerd rank
21/ 100
Median analyst target
$4.00
Analysts covering
9
Revenue$0.0
Operating income−$34.0M
Net income−$32.5M
Free cash flow−$18.9M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.8%
1M
+11.4%
YTD
−80.5%
1Y
−74.0%
From 52W high
−85.5%
From 52W low
+22.2%
$1
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores enGene Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
21/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
60
Volatility
52
Quality
50
Growth
39
Revisions
25
Momentum
22
Value
20
Issuance
19

Accruals (60): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26ENGNHigh $6.00Median $4.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
6
Buy
3
Hold
0
Sell
$2.00
Low
$4.00
Median
$6.00
High

The green dot is the last close — the median target sits +127.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026Leerink PartnersUpgradeOutperform$5.00
12 Nov 2026Piper SandlerUpgradeOverweight$4.00
12 Nov 2026Wells FargoUpgradeOverweight$2.00 → $6.00
9 Sept 2026CitizensReiteratesMarket Perform—
8 Sept 2026HC Wainwright & Co.ReiteratesBuy$4.00
18 June 2026Morgan StanleyDowngradeUnderweight—
16 June 2026HC Wainwright & Co.MaintainsBuy$6.00 → $4.00
14 May 2026UBSMaintainsNeutral—
8 May 2026CitizensDowngradeMarket Perform—
8 May 2026GuggenheimDowngradeNeutral—
8 May 2026HC Wainwright & Co.MaintainsBuy—
8 May 2026Piper SandlerDowngradeNeutral—
8 May 2026Wells FargoDowngradeEqual-Weight—
13 Apr 2026WBB SecuritiesInitiatesBuy—
11 Mar 2026OppenheimerMaintainsOutperform—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025CitizensMaintainsMarket Outperform—
12 Nov 2025Morgan StanleyMaintainsOverweight—
12 Nov 2025OppenheimerReiteratesOutperform—
12 Nov 2025UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ENGN.

Market Radar

This page is one stock. Monday covers all of them.

ENGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ENGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, enGene Therapeutics, Inc. returned −74.0% against +9.2% for the S&P 500, dividends included.

ENGN vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26ENGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
6
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−60.5%

Higher than 19% of US stocks

Return on assets
−32.0%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • enGene Therapeutics, Inc. has a market value of $117.9M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$130.4M.

  • Free cash flow in the twelve months to 31 July 2026: −$104.0M.

  • Shares outstanding: 67.0M.

  • enGene Therapeutics, Inc. employs 81 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ENGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENGNenGene Therapeutics, Inc.$117.9M21
NRXPNRX Pharmaceuticals, Inc.$124.1M19
CDXSCodexis, Inc.$123.7M40
MGNXMacroGenics, Inc.$125.2M87
ALXOALX Oncology Holdings, Inc.$125.4M40
FATEFate Therapeutics, Inc.$122.1M85
NTHINeOnc Technologies Holdings, Inc.$119.8M31

Take a look at ENGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own enGene Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ENGN

What is the ENGN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering enGene Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $2 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENGN stock a buy right now?

Of the 9 analysts covering enGene Therapeutics, Inc., 6 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks enGene Therapeutics, Inc. 21 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENGN?

As at 18 Nov 2026, enGene Therapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (60 of 100).

Will ENGN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks enGene Therapeutics, Inc. 21 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENGN stock forecast for 2030?

No analyst covering enGene Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $6 over the next 12 months.

How has ENGN stock performed over the past year?

enGene Therapeutics, Inc. returned -74.0% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does enGene Therapeutics, Inc. do?

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs.

Company

About enGene Therapeutics, Inc.

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with significant unmet medical needs. The company’s work centers on its proprietary DDX delivery platform, which is designed to deliver DNA and RNA-based therapies directly to mucosal tissues and other target organs. Its lead product candidate, detalimogene voraplasmid, is being developed as a monotherapy for non-muscle invasive bladder cancer, including difficult-to-treat high-risk cases. enGene Therapeutics Inc. also advances a broader pipeline of gene therapy programs aimed at localized treatment delivery in oncology and other therapeutic areas. Based in Montreal, Canada, the company plays a specialized role in the biotechnology market by pursuing tissue-targeted genetic therapies that seek to address complex diseases through precision delivery approaches.

CEO Mr. Ronald H. W. Cooper · 81 employees · Canada · https://www.engene.com